The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Open accessAbstract
BACKGROUND: Ten patients with breast cancer and a breast cancer susceptibility gene 1 (BRCA1) mutation, who presented with stages I to III breast cancer between December 2006 and 2007, were treated with four cycles of neoadjuvant cisplatin, followed by mastectomy and conventional chemotherapy. METHODS: The excised breast tissue and lymph nodes were examined for the presence of residual disease. RESULTS: Pathologic complete response was observed in nine patients (90%). CONCLUSIONS: Platinum-based chemotherapy appears to be effective in a high proportion of patients with BRCA1-associated breast cancers. Clinical trials are now warranted to determine the optimum treatment for this subgroup of breast cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,171
Lakhani, S. R., Jacquemier, J., Sloane, J. P., Gusterson, B. A., Anderson, T. J., van de Vijver, M. J., Farid, L. M., Venter, D., Antoniou, A., Storfer-Isser, A., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.15.1138 · Cited by 707
Bhattacharyya, A., Ear, U. S., Koller, B. H., Weichselbaum, R. R., & Bishop, D. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000276200 · Cited by 583
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.
Quinn, J. E., Kennedy, R. D., Mullan, P. B., Gilmore, P. M., Carty, M., Johnston, P. G., & Harkin, D. P. (2003) · PubMed · Cited by 464
Improved survival in women with BRCA‐associated ovarian carcinoma
Cass, I., Baldwin, R. L., Varkey, T., Moslehi, R., Narod, S. A., & Karlan, B. Y. (2003) · Cancer · doi:10.1002/cncr.11310 · Cited by 433
Self-citationThe Role of BRCA1 in the Cellular Response to Chemotherapy
Kennedy, R. D., Quinn, J. E., Mullan, P. B., Johnston, P. G., & Harkin, D. P. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh312 · Cited by 430
Gralow, J. R., Burstein, H. J., Wood, W., Hortobagyi, G. N., Gianni, L., von Minckwitz, G., Buzdar, A. U., Smith, I. E., Symmans, W. F., Singh, B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3510 · Cited by 400
Cancer Stem Cells Contribute to Cisplatin Resistance in Brca1/p53 –Mediated Mouse Mammary Tumors
Shafee, N., Smith, C. R., Wei, S., Kim, Y., Mills, G. B., Hortobagyi, G. N., Stanbridge, E. J., & Lee, E. Y.-H. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5480 · Cited by 308
Robson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research · doi:10.1186/bcr658 · Cited by 307
Clinical Outcomes of Breast Cancer in Carriers of BRCA1 and BRCA2 Mutations
Rennert, G., Bisland-Naggan, S., Barnett-Griness, O., Bar-Joseph, N., Zhang, S., Rennert, H. S., & Narod, S. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070608 · Cited by 302
Self-citationEstrogen Receptor Status in BRCA1 - and BRCA2 -Related Breast Cancer
Foulkes, W. D., Metcalfe, K., Sun, P., Hanna, W. M., Lynch, H. T., Ghadirian, P., Tung, N., Olopade, O. I., Weber, B. L., McLennan, J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-1061 · Cited by 293
Self-citationDixon, J. M. (2012) · Medical Entomology and Zoology · Cited by 287
Platinum-based chemotherapy in metastatic breast cancer: current status
Decatris, M. P., Sundar, S., & O’Byrne, K. J. (2004) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00139-7 · Cited by 211
A high proportion of founder BRCA1 mutations in Polish breast cancer families
Górski, B., Jakubowska, A., Huzarski, T., Byrski, T., Gronwald, J., Grzybowska, E., Mackiewicz, A., Stawicka, M., Bębenek, M., Sorokin, D., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20162 · Cited by 194
Self-citationTargeting the DNA repair defect of BRCA tumours
TURNER, N., TUTT, A., & ASHWORTH, A. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.03.006 · Cited by 164
Chabalier, C., Lamare, C., Racca, C., Privat, M., Valette, A., & Larminat, F. (2006) · Cell Cycle · doi:10.4161/cc.5.9.2726 · Cited by 159
Tilanus‐Linthorst, M. M. A., Obdeijn, I.-M., Hop, W. C. J., Causer, P. A., Leach, M. O., Warner, E., Pointon, L. J., Hill, K. A., Klijn, J. G. M., Warren, R. M. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0689 · Cited by 113
Zhou, C., Smith, J. L., & Liu, J. (2003) · Oncogene · doi:10.1038/sj.onc.1206319 · Cited by 74
Cited by
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1001389 · Cited by 4,157
Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., Szallasi, Z., Barry, W. T., Winer, E. P., Tung, N. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2477 · Cited by 1,136
DNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051
Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., Kuzma, C. S., Pluard, T. J., Somlo, G., Port, E. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,013
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., Juul, N., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 981
Metadata
- Authors
- Byrski, T., Huzarski, T., Dent, R., Gronwald, J., Zuziak, D., Cybulski, C., Kladny, J., Gorski, B., Lubinski, J., & Narod, S. A.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2008-07-23
- Volume
- 115
- Issue
- 2
- Pages
- 359-363
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2146717458
- Cited by
- 340
- References
- 19
- FWCI
- 16.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.